Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2006

Open Access 01-12-2006 | Primary research

Expression of EpCAM in uveal melanoma

Authors: Danilo N Odashiro, Alexandre N Odashiro, Patrícia R Pereira, Katyanne Godeiro, Emilia Antecka, Sebastian Di Cesare, Miguel N Burnier Jr

Published in: Cancer Cell International | Issue 1/2006

Login to get access

Abstract

Background

Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults, and nearly 40% of UM will develop metastasis that will ultimately lead to death. The Epithelial Cell Adhesion Molecule (EpCAM) is a type I transmembrane glycoprotein expressed by carcinomas of head and neck, ovary, colon, breast, kidney and lung. Recently, antibodies against EpCAM such as Edrecolomab and Catumaxomab were developed, and clinical trials with these antibodies have been used in several types of neoplasia. We studied the expression of EpCAM in UM.

Methods

25 enucleated formalin-fixed, paraffin-embedded UM specimens were immunostained for EpCAM. Histopathological analysis of the specimens with regards to prognostic factors such as cell type, largest (linear) tumor dimension, number of mitotic figures, scleral invasion and tumor infiltrating lymphocytes were done.

Results

None of them was positive for this EpCAM.

Conclusion

In our report, UM did not express EpCAM. Therefore, it is not a helpful immunohistochemical marker to predict the behavior of UM. Further studies are needed to verify if EpCAM could also be related with prognosis and treatment of UM.
Appendix
Available only for authorised users
Literature
1.
Singh AD, Bergman L, Seregard S: Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005, 18: 75-84, viii. 10.1016/j.ohc.2004.07.002.CrossRefPubMed
2.
Korabiowska M, Ruschenburg I, Schulz H, Steinacker A, Bortkiewicz P, Sevenich M, Brinck U, Cordon-Cardo C, Fischer G: Cytokeratin expression correlates with aneuploidy in cytological specimens of melanoma metastases. Anticancer Res. 2005, 25: 2789-2792.PubMed
3.
Hendrix MJ, Seftor EA, Seftor RE, Gardner LM, Boldt HC, Meyer M, Pe'er J, Folberg R: Biologic determinants of uveal melanoma metastatic phenotype: role of intermediate filaments as predictive markers. Lab Invest. 1998, 78: 153-163.PubMed
4.
Pereira PR, Odashiro AN, Marshall JC, Correa ZM, Belfort R, Burnier Jr MN: The role of c-kit and Imatinib Mesylate in uveal melanoma. J Carcinog. 2005, 4: 19-10.1186/1477-3163-4-19.PubMedCentralCrossRefPubMed
5.
Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV: The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol. 2003, 163: 2139-2148.PubMedCentralCrossRefPubMed
6.
Balzar M, Winter MJ, de Boer CJ, Litvinov SV: The biology of the 17-1A antigen (Ep-CAM). J Mol Med. 1999, 77: 699-712. 10.1007/s001099900038.CrossRefPubMed
7.
litinov SVV: Ep-cam:A Human Epithelial Antigen Is a Homophilic Cell-Cell Adhesion Molecule. The Journal of Cell Biology. 1994, 125: 437-446. 10.1083/jcb.125.2.437.CrossRef
8.
de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV: Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol. 1999, 188: 201-206. 10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO;2-8.CrossRefPubMed
9.
Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE: EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 2004, 64: 5818-5824. 10.1158/0008-5472.CAN-04-0754.CrossRefPubMed
10.
Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH: Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer. 2005, 92: 1767-1772. 10.1038/sj.bjc.6602519.PubMedCentralCrossRefPubMed
11.
Gronau SS, Schmitt M, Thess B, Reinhardt P, Wiesneth M, Schmitt A, Riechelmann H: Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract. Head Neck. 2005, 27: 376-382. 10.1002/hed.20170.CrossRefPubMed
12.
M. Sebastian AS: P-974 Treatment of non-small cell lung cancer (NSCLC) patients with the trifunctional bispecific antibody catumaxomab (removab®) (anti-EpCAM × anti-CD3: Results of a phase I study. Lung Cancer. 2005, Volume 49: S376-10.1016/S0169-5002(05)81467-9.CrossRef
13.
Kirchner EM, Gerhards R, Voigtmann R: Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells. Ann Oncol. 2002, 13: 1044-1048. 10.1093/annonc/mdf184.CrossRefPubMed
14.
Hartung G, Hofheinz RD, Dencausse Y, Sturm J, Kopp-Schneider A, Dietrich G, Fackler-Schwalbe I, Bornbusch D, Gonnermann M, Wojatschek C, Lindemann W, Eschenburg H, Jost K, Edler L, Hochhaus A, Queisser W: Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie. 2005, 28: 347-350. 10.1159/000084595.CrossRefPubMed
15.
P Wimberger*1 AB, J Pfisterer6 ML, M Biakhov10 VM: Tolerability and efficacy of the trifunctional antibody removab®(anti-EpCAM x anti-CD3) in patients with malignant ascites due toovarian cancer: Results of a phase I/II study. Cancer Cell International. 2004, 4(Suppl 1):: S3-10.1186/1475-2867-4-S1-S3.CrossRef
16.
Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O: The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene. 2004, 23: 5748-5758. 10.1038/sj.onc.1207610.CrossRefPubMed
17.
Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S: Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004, 35: 122-128. 10.1016/j.humpath.2003.08.026.CrossRefPubMed
18.
Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, Kochli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gastl G: High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004, 86: 207-213. 10.1023/B:BREA.0000036787.59816.01.CrossRefPubMed
19.
Joo M, Kim H, Kim MK, Yu HJ, Kim JP: Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma. J Gastroenterol Hepatol. 2005, 20: 1039-1045.CrossRefPubMed
20.
Kim YC, Lee MG, Choe SW, Lee MC, Chung HG, Cho SH: Acral lentiginous melanoma: an immunohistochemical study of 20 cases. Int J Dermatol. 2003, 42: 123-129. 10.1046/j.1365-4362.2003.01583.x.CrossRefPubMed
21.
Ben-Izhak O, Stark P, Levy R, Bergman R, Lichtig C: Epithelial markers in malignant melanoma. A study of primary lesions and their metastases. Am J Dermatopathol. 1994, 16: 241-246.CrossRefPubMed
22.
Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002, 360: 671-677. 10.1016/S0140-6736(02)09836-7.CrossRefPubMed
23.
M.Sebastian AS, R Wiewrodt HL: Treatment of non-small cell lung cancer (NSCLC) patients wlththe trifunctional blspecific antibody catumaxomab(removab ®)(antI-EpCAM x antI-CD3): Results of a phase I study. 2005,
Metadata
Title
Expression of EpCAM in uveal melanoma
Authors
Danilo N Odashiro
Alexandre N Odashiro
Patrícia R Pereira
Katyanne Godeiro
Emilia Antecka
Sebastian Di Cesare
Miguel N Burnier Jr
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2006
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-6-26

Other articles of this Issue 1/2006

Cancer Cell International 1/2006 Go to the issue

Primary research

Transfection of oral squamous cell carcinoma with human papillomavirus-16 induces proliferative and morphological changes in vitro

Primary research

Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells

Primary research

Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells

Primary research

Cytogenetic characterization and H-ras associated transformation of immortalized human mammary epithelial cells

Primary research

Mast cells dysregulate apoptotic and cell cycle genes in mucosal squamous cell carcinoma

Primary research

Decreased intracellular zinc in human tumorigenic prostate epithelial cells: a possible role in prostate cancer progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits